427 related articles for article (PubMed ID: 11345193)
1. Mechanisms of transformation by the BCR/ABL oncogene.
Sattler M; Griffin JD
Int J Hematol; 2001 Apr; 73(3):278-91. PubMed ID: 11345193
[TBL] [Abstract][Full Text] [Related]
2. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies for chronic myelogenous leukemia.
Jahagirdar BN; Miller JS; Shet A; Verfaillie CM
Exp Hematol; 2001 May; 29(5):543-56. PubMed ID: 11376866
[TBL] [Abstract][Full Text] [Related]
4. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Giles FJ; Cortes JE; Kantarjian HM
Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
[TBL] [Abstract][Full Text] [Related]
5. Molecular biology of chronic myeloid leukemia.
Maru Y
Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
[TBL] [Abstract][Full Text] [Related]
6. Molecular and cellular bases of chronic myeloid leukemia.
Chen Y; Peng C; Li D; Li S
Protein Cell; 2010 Feb; 1(2):124-32. PubMed ID: 21203982
[TBL] [Abstract][Full Text] [Related]
7. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
8. Switching off oncogenic signals in chronic myeloid leukaemia.
Melo J; Barnes DJ
Hematol J; 2004; 5 Suppl 3():S183-7. PubMed ID: 15190305
[No Abstract] [Full Text] [Related]
9. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
10. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
11. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
12. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
Sattler M; Salgia R
Cytokine Growth Factor Rev; 1997 Mar; 8(1):63-79. PubMed ID: 9174663
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.
Van Etten RA
Leuk Res; 2004 May; 28 Suppl 1():S21-8. PubMed ID: 15036938
[TBL] [Abstract][Full Text] [Related]
15. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
16. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ; MacPartlin M; Bumm T; Goss VL; O'Hare T; Lee KA; Corbin AS; Stoffregen EP; Smith C; Johnson K; Moseson EM; Wood LJ; Polakiewicz RD; Druker BJ; Deininger MW
Mol Cell Biol; 2006 Aug; 26(16):6082-93. PubMed ID: 16880519
[TBL] [Abstract][Full Text] [Related]
17. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
[TBL] [Abstract][Full Text] [Related]
18. Genomic instability: The cause and effect of BCR/ABL tyrosine kinase.
Skorski T
Curr Hematol Malig Rep; 2007 May; 2(2):69-74. PubMed ID: 20425353
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of transformation by the BCR-ABL oncogene.
Sattler M; Griffin JD
Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]